



**Technology:** Insulin glargine is a long-acting recombinant human insulin analog that helps to control blood sugar levels in patients with diabetes.

## Insulin Glargine Timeline



## Insulin Glargine Challenged Claim Types in IPR and Litigation\*



\*Litigation Defendants alleged to infringe at least these claims in complaints/amended complaints. Joinder counted separately.

# Spotlight On: Insulin Glargine

April 30, 2024

|           | <i>Sanofi v. Eli Lilly</i><br>1:14-cv-00113 (D. Del.)<br>Settled | <i>Sanofi v. Eli Lilly</i><br>1:14-cv-00884 (D. Del.)<br>Settled | <i>Sanofi v. Merck</i><br>1:16-cv-00812 (D. Del.)<br>Stipulated dismissal | <i>Sanofi v. Merck</i><br>2:17-cv-05914 (D.N.J.)<br>Stipulated dismissal | <i>Sanofi v. Mylan</i><br>2:17-cv-09105 (D.N.J.)<br>Claims not infringed, but invalid<br>Appeal 21-1262<br>Dismissed as Moot | <i>Mylan v. Sanofi</i><br>IPR2017-01526<br>FWD (All instituted claims unpatentable);<br>Appeal 19-1368<br>Affirmed, Rehearing denied; Sup. Ct. 19-1451<br>Cert Denied | <i>Mylan v. Sanofi</i><br>IPR2017-01528<br>FWD (All instituted claims unpatentable);<br>Appeal 19-1369<br>Affirmed, Rehearing denied; Sup. Ct. 19-1451<br>Cert Denied | <i>Mylan v. Sanofi</i><br>IPR2018-01670<br>FWD (Instituted claim unpatentable)<br>Appeal 20-1871<br>Pending<br><i>Pfizer v. Sanofi</i><br>IPR2019-00979<br>(Joinder denied) FWD (All instituted claims unpatentable); Appeal 20-2159 Affirmed | <i>Mylan v. Sanofi</i><br>IPR2018-01675<br>IPR2018-01676<br><i>Pfizer v. Sanofi</i><br>IPR2019-00977<br>IPR2019-00978 Joined<br>FWD (All instituted claims unpatentable);<br>Appeals 20-2029<br>Dismissed as Moot, 20-2032 Affirmed    | <i>Mylan v. Sanofi</i><br>IPR2018-01677<br>Terminated prior to institution decision;<br>Refiled as IPR2019-00122,<br><i>Pfizer v. Sanofi</i><br>IPR2019-00982 Joined<br>FWD (All instituted claims unpatentable);<br>Appeal 20-2034<br>Dismissed as Moot | <i>Mylan v. Sanofi</i><br>IPR2018-01678<br>IPR2018-01679<br><i>Pfizer v. Sanofi</i><br>IPR2019-00980<br>IPR2019-00981 Joined<br>FWD (All instituted claims unpatentable);<br>Appeals 20-2033, 20-2066 Affirmed |
|-----------|--|--|---|--|--|---|---|---|--|--|--|
| 7,476,652 | x  | x  | x   | x  | x  | x   |   |   |  |  |  |
| 7,713,930 | x  | x  | x   | x  | x  |   | x   |   |  |  |  |
| 7,918,833 |  | x  | x   |  | x  |   |   |   |  |  |  |
| 8,512,297 |  | x  | x   |  | x  |   |   |   |  |  |  |
| 8,556,864 | x  | x  | x   |  | x  |   |   |   |  |  |  |
| 8,603,044 | x  | x  | x   |  | x  |   |   |   | x  |  |  |
| 8,679,069 | x  | x  | x   |  | x  |   |   | x   |  |  |  |
| 8,992,486 |  |  | x   |  | x  |   |   |   |  | x  | x  |
| 9,011,391 |  |  | x   |  | x  |   |   |   |  |  |  |
| 9,233,211 |  |  | x   |  | x  |   |   |   |  |  |  |
| 9,408,979 |  |  |   |  | x  |   |   |   |  |  |  |
| 9,457,152 |  |  | x   |  |  |   |   |   |  |  |  |
| 9,486,587 |  |  | x   |  |  |   | <i>Mylan v. Sanofi</i><br>IPR2019-01658<br>Institution denied   | <i>Mylan v. Sanofi</i><br>IPR2019-01657<br>FWD (All instituted claims unpatentable);<br>Appeal 21-1981<br>Reversed  | <i>Mylan v. Sanofi</i><br>IPR2018-01680<br>IPR2018-01682<br><i>Pfizer v. Sanofi</i><br>IPR2019-01022<br>IPR2019-01023 Joined<br>FWD (All instituted claims unpatentable);<br>Appeals 20-2068<br>Affirmed, 20-2069<br>Dismissed as Moot | <i>Mylan v. Sanofi</i><br>IPR2018-01696<br>Institution denied  | <i>Mylan v. Sanofi</i><br>IPR2018-01684<br><i>Pfizer v. Sanofi</i><br>IPR2019-00987<br>Joined<br>FWD (Some instituted claims unpatentable);<br>Appeal 20-2071<br>Affirmed, 20-2139 & 20-2144 Withdrawn         |
| 9,526,844 |  |  | x   |  | x  |   |   |   | x  | x  |  |
| 9,533,105 |  |  | x   |  | x  |   |   |   |  |  |  |
| 9,561,331 |  |  |   |  | x  |   |   |   |  |  |  |
| 9,592,348 |  |  | x   |  |  |   |   |   |  |  |  |
| 9,604,008 |  |  | x   |  | x  |   |   |   |  |  | x  |
| 9,604,009 |  |  |   |  | x  |   |   |   |  |  |  |
| 9,610,409 |  |  |   |  | x  |   |   |   |  |  |  |
| 9,623,189 |  |  |   |  | x  |   |   |   |  |  |  |
| RE47,614  |  |  |   |  |  |   | x   | x   |  |  |  |